Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression
V. Kh. Khavinson, A. Yu. Solovyev, S. I. Tarnovskaya, N. S. Linkova · 2013 · Biology Bulletin Reviews 3(6):451–455
What does this source report?
Mechanistic review with a table of 15 short peptides on page 453. Tissue labels in the research map are the authors’ proposed targets, not established clinical indications.
- Population and setting
- Review of earlier research
- Evidence type
- Review
- Preparation
- See the original report; formulation details require verification.
- Source language
- English
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Source-linked does not mean a completed risk-of-bias review.
- A review is not an independent clinical replication; proposed mechanisms do not establish efficacy or safety.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Author-hosted English PDF and its peptide table checked. Each cited experiment remains a separate appraisal task.
Recorded source-check date: 2026-09-27. This date does not imply a completed systematic review.
Cite and trace this record
Original source: V. Kh. Khavinson, A. Yu. Solovyev, S. I. Tarnovskaya, N. S. Linkova. Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression Biology Bulletin Reviews 3(6):451–455 2013.
Molekul research summary: https://molekul.io/research/short-peptides-2013. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Thymogen
EW is discussed in the thymus-derived research program. Thymalin extract outcomes cannot be assigned to this defined peptide.
Vilon
A peptide research entry in the Khavinson evidence map. Direct studies, related extract findings, institute reports and unresolved claims are distinguished below.
Normophthal
Listed in the 2013 short-peptide review under the authors’ proposed retina target. This historical label is not an established indication. Underlying studies need individual review.
Cartalax
AED research is distinct from PCC. The linked animal and cell papers, and a small patent-reported human comparison, do not establish cartilage regeneration.
Pinealon
A peptide research entry in the Khavinson evidence map. Direct studies, related extract findings, institute reports and unresolved claims are distinguished below.
Chonluten
A peptide research entry in the Khavinson evidence map. Direct studies, related extract findings, institute reports and unresolved claims are distinguished below.
Vesugen
A peptide research entry in the Khavinson evidence map. Direct studies, related extract findings, institute reports and unresolved claims are distinguished below.
Epitalon
AEDG was detected in pineal complex, but the long-term Epithalamin patient studies concern the extract. Synthetic-peptide effects require their own evidence.
Prostamax
Listed in the 2013 short-peptide review under the authors’ proposed prostate target. This historical label is not an established indication. Underlying studies need individual review.
Livagen
The liver literature discusses Ventvil extract and KEDA/Livagen separately. Experimental fibrosis and hepatitis findings do not establish human treatment benefit.
Cortagen
Listed in the 2013 short-peptide review under the authors’ proposed brain target. This historical label is not an established indication. Underlying studies need individual review.
Pancragen
A peptide research entry in the Khavinson evidence map. Direct studies, related extract findings, institute reports and unresolved claims are distinguished below.
Cardiogen
The AEDR rat-infarction finding traces to a patent cited by the cardiovascular review. The molecular link to heart complex remains review-reported here.
Testagen
Catalogue entry with identity and compound-specific evidence unresolved. No sequence or clinical outcome is asserted from commercial naming alone.
Bronchogen
Listed in the 2013 short-peptide review under the authors’ proposed bronchi target. This historical label is not an established indication. Underlying studies need individual review.